Rallybio Corporation
Rallybio Corporation (RLYB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · RLYB · as of Jun 9, 2026
Key Statistics
Explore Rallybio Corporation Data
rlyb stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 50.0%
Competitors & Peers
rlyb competitorsRLYB
BOLD
CVKD
IBIO
INTS
ITRMStock Performance
Full HistoryAbout Rallybio Corporation
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most adva…
what is rallybio corporation · rlyb stock overview · rallybio corporation company profile · who is rallybio corporation ceo · rlyb NASDAQ · rallybio corporation headquarters · rallybio corporation business segments
About Stock Overview & Key Data
Rallybio Corporation (RLYB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 29, 2021. As of the latest trading session, RLYB stock price is $15.91, with a market capitalization of $84.3M. The stock has returned +430.33% over the past 12 months and +189.80% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Rallybio Corporation stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Rallybio Corporation reported revenue of $858000.00 and net income of -$9.0M. For detailed data — including Rallybio Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Rallybio Corporation (RLYB) stock price is $15.91. The stock is traded on NASDAQ under the ticker symbol RLYB. The 52-week range is $2.40 – $17.57.